Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.

Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr.

J Immunother Cancer. 2019 Jun 27;7(1):163. doi: 10.1186/s40425-019-0625-x.

2.

Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease.

Barrett MJ, Sperling SA, Blair JC, Freeman CS, Flanigan JL, Smolkin ME, Manning CA, Druzgal TJ.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1251-1256. doi: 10.1136/jnnp-2019-320450. Epub 2019 Jun 7.

PMID:
31175168
3.

Functional and Cognitive Status in Clostridium difficile Infection in the Hospitalized Elderly: a Retrospective Study of Two Sites.

Fernandez-Cotarelo MJ, Nagy-Agren SE, Smolkin ME, Jimenez-Diez-Canseco L, Perez-Pomata MT, Shenal BV, Warren CA.

J Gen Intern Med. 2019 Aug;34(8):1392-1393. doi: 10.1007/s11606-019-04935-6. No abstract available.

PMID:
30891689
4.

Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.

Wentworth BJ, Buerlein RCD, Tuskey AG, Overby MA, Smolkin ME, Behm BW.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy102. [Epub ahead of print]

PMID:
29668917
5.

Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease.

Barrett MJ, Blair JC, Sperling SA, Smolkin ME, Druzgal TJ.

Neurology. 2018 May 1;90(18):e1618-e1626. doi: 10.1212/WNL.0000000000005421. Epub 2018 Apr 4.

PMID:
29618627
6.

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA, Smith KT, Olson WC, Fanous IS, Nail CJ, Brenin CM, Hall EH, Slingluff CL Jr.

J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.

7.

Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia.

Barrett MJ, Smolkin ME, Flanigan JL, Shah BB, Harrison MB, Sperling SA.

Parkinsonism Relat Disord. 2017 Oct;43:56-60. doi: 10.1016/j.parkreldis.2017.07.011. Epub 2017 Jul 15.

PMID:
28735797
8.

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL.

Oncoimmunology. 2016 Sep 20;5(11):e1235107. doi: 10.1080/2162402X.2016.1235107. eCollection 2016.

9.

More than Just the Number of Brain Metastases: Evaluating the Impact of Brain Metastasis Location and Relative Volume on Overall Survival After Stereotactic Radiosurgery.

Emery A, Trifiletti DM, Romano KD, Patel N, Smolkin ME, Sheehan JP.

World Neurosurg. 2017 Mar;99:111-117. doi: 10.1016/j.wneu.2016.11.119. Epub 2016 Dec 2.

PMID:
27919761
10.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. doi: 10.1007/s00262-016-1880-z. Epub 2016 Aug 13.

11.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13.

12.

Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center.

Pierson TM, Tebit EV, El Sayed A, Smolkin ME, Dillon PM.

Breast J. 2016 Jul;22(4):447-50. doi: 10.1111/tbj.12604. Epub 2016 May 3.

PMID:
27143519
13.

Prognostic value of albumin in patients with head and neck cancer.

Danan D, Shonka DC Jr, Selman Y, Chow Z, Smolkin ME, Jameson MJ.

Laryngoscope. 2016 Jul;126(7):1567-71. doi: 10.1002/lary.25877. Epub 2016 Feb 10.

PMID:
26864349
14.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW.

Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.

15.

Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.

Ramirez AG, Wages NA, Hu Y, Smolkin ME, Slingluff CL Jr.

Cancer Immunol Immunother. 2015 Dec;64(12):1531-9. doi: 10.1007/s00262-015-1758-5. Epub 2015 Sep 21.

16.

The Risk Factors of Readmission in Postoperative Gynecologic Oncology Patients at a Single Institution.

Nakayama JM, Ou JP, Friedman C, Smolkin ME, Duska LR.

Int J Gynecol Cancer. 2015 Nov;25(9):1697-703. doi: 10.1097/IGC.0000000000000535.

PMID:
26332390
17.

Impact of blood transfusions on patients with head and neck cancer undergoing free tissue transfer.

Danan D, Smolkin ME, Varhegyi NE, Bakos SR, Jameson MJ, Shonka DC Jr.

Laryngoscope. 2015 Jan;125(1):86-91. doi: 10.1002/lary.24847. Epub 2014 Aug 14.

PMID:
25124183
18.

Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.

Hu Y, Smolkin ME, White EJ, Petroni GR, Neese PY, Slingluff CL Jr.

Ann Surg Oncol. 2014 Nov;21(12):3978-84. doi: 10.1245/s10434-014-3794-3. Epub 2014 May 20.

19.

Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.

Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW, Chianese-Bullock KA, Slingluff CL Jr.

Cancer Immunol Immunother. 2014 Aug;63(8):779-86. doi: 10.1007/s00262-014-1551-x. Epub 2014 Apr 23. Erratum in: Cancer Immunol Immunother. 2014 Oct;63(10):1113.

20.

Factors related to decision making and substance use in adolescent survivors of childhood cancer: a presenting clinical profile.

Hollen PJ, Tyc VL, Shannon SV, Donnangelo SF, Hobbie WL, Hudson MM, O'Laughlen MC, Smolkin ME, Petroni GR.

J Cancer Surviv. 2013 Sep;7(3):500-10. doi: 10.1007/s11764-013-0287-5. Epub 2013 May 28.

PMID:
23712611
21.

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.

Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr.

Cancer Immunol Immunother. 2013 Jul;62(7):1149-59. doi: 10.1007/s00262-013-1435-5. Epub 2013 May 9.

22.

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).

Slingluff CL Jr, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ.

Clin Cancer Res. 2013 Jul 1;19(13):3611-20. doi: 10.1158/1078-0432.CCR-12-3919. Epub 2013 Apr 25.

23.

A substance use decision aid for medically at-risk adolescents: results of a randomized controlled trial for cancer-surviving adolescents.

Hollen PJ, Tyc VL, Donnangelo SF, Shannon SV, O'Laughlen MC, Hinton I, Smolkin ME, Petroni GR.

Cancer Nurs. 2013 Sep-Oct;36(5):355-67. doi: 10.1097/NCC.0b013e31827910ba.

24.

Predictors of Retention and BMI Loss or Stabilization in Obese Youth Enrolled in a Weight Loss Intervention.

Walker SE, Smolkin ME, O'Leary ML, Cluett SB, Norwood VF, Deboer MD, Gurka MJ.

Obes Res Clin Pract. 2012;6(4):e330-e339. Epub 2011 Sep 28.

25.

Infrared thermography of cutaneous melanoma metastases.

Shada AL, Dengel LT, Petroni GR, Smolkin ME, Acton S, Slingluff CL Jr.

J Surg Res. 2013 Jun 1;182(1):e9-e14. doi: 10.1016/j.jss.2012.09.022. Epub 2012 Sep 27.

26.

Predictors of retention and BMI loss or stabilization in obese youth enrolled in a weight loss intervention.

Walker SE, Smolkin ME, O'Leary ML, Cluett SB, Norwood VF, Deboer MD, Gurka MJ.

Obes Res Clin Pract. 2012 Oct-Dec;6(4):e263-346. doi: 10.1016/j.orcp.2011.08.157.

PMID:
24331594
27.

Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia.

Giugale LE, Di Santo N, Smolkin ME, Havrilesky LJ, Modesitt SC.

Gynecol Oncol. 2012 Nov;127(2):326-31. doi: 10.1016/j.ygyno.2012.08.014. Epub 2012 Aug 19.

PMID:
22910692
28.

Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ.

PLoS One. 2012;7(5):e36669. doi: 10.1371/journal.pone.0036669. Epub 2012 May 10.

29.

Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences.

McClain SE, Mayo KB, Shada AL, Smolkin ME, Patterson JW, Slingluff CL Jr.

Int J Dermatol. 2012 Apr;51(4):420-6. doi: 10.1111/j.1365-4632.2011.05066.x.

30.

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL Jr.

Cancer Res. 2012 Mar 1;72(5):1070-80. doi: 10.1158/0008-5472.CAN-11-3218. Epub 2012 Jan 19.

31.

Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW.

J Clin Oncol. 2011 Jul 20;29(21):2924-32. doi: 10.1200/JCO.2010.33.8053. Epub 2011 Jun 20.

32.

Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera.

Dengel LT, More MJ, Judy PG, Petroni GR, Smolkin ME, Rehm PK, Majewski S, Williams MB, Slingluff CL Jr.

Ann Surg. 2011 Apr;253(4):774-8. doi: 10.1097/SLA.0b013e3181f9b709.

33.

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.

Olson WC, Smolkin ME, Farris EM, Fink RJ, Czarkowski AR, Fink JH, Chianese-Bullock KA, Slingluff CL Jr.

J Transl Med. 2011 Mar 8;9:26. doi: 10.1186/1479-5876-9-26.

34.

Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.

Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr.

J Transl Med. 2010 Aug 20;8:79. doi: 10.1186/1479-5876-8-79.

35.

Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.

Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, Galeassi N, Neese PY, Grosh WW, Nail CJ, Ross M, von Mehren M, Haas N, Boisvert ME, Kirkwood JM.

J Immunother. 2010 Jul-Aug;33(6):630-8. doi: 10.1097/CJI.0b013e3181e311ac.

36.

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA.

Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10.

37.

Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.

Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr.

Cancer Immunol Immunother. 2010 Mar;59(3):465-72. doi: 10.1007/s00262-009-0765-9. Epub 2009 Sep 16.

38.

Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.

Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT.

Am J Surg Pathol. 2008 Nov;32(11):1608-12. doi: 10.1097/PAS.0b013e31816d71c4.

PMID:
18753946
39.

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK.

Clin Cancer Res. 2007 Nov 1;13(21):6386-95.

40.
41.

Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?

Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D.

BJU Int. 2007 Apr;99(4):780-5.

42.

Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer.

Fletcher SG, Mills SE, Smolkin ME, Theodorescu D.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1092-9. Epub 2006 Sep 11.

PMID:
16965872
43.

Stage IB nonsmall cell lung cancers: are they all the same?

Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR.

Ann Thorac Surg. 2006 Jun;81(6):1958-62; discussion 1962.

PMID:
16731113
44.

A comparison of developmental versus functional assessment in the rehabilitation of young children.

Long CE, Blackman JA, Farrell WJ, Smolkin ME, Conaway MR.

Pediatr Rehabil. 2005 Apr-Jun;8(2):156-61.

PMID:
16089256
46.

Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients.

Cragun WC, Yamshchikov GV, Bissonette EA, Smolkin ME, Eastham S, Petroni GR, Schrecengost RS, Woodson EM, Slingluff CL Jr.

Cancer Immunol Immunother. 2005 Nov;54(11):1095-105. Epub 2005 May 12.

PMID:
15889250
47.
48.

Contribution of Burkholderia cenocepacia flagella to infectivity and inflammation.

Urban TA, Griffith A, Torok AM, Smolkin ME, Burns JL, Goldberg JB.

Infect Immun. 2004 Sep;72(9):5126-34.

49.

Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists.

Vomastek T, Schaeffer HJ, Tarcsafalvi A, Smolkin ME, Bissonette EA, Weber MJ.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):6981-6. Epub 2004 Apr 26.

50.

The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms.

Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE.

Clin Genet. 2002 Jul;62(1):53-9.

PMID:
12123488

Supplemental Content

Loading ...
Support Center